Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
In response to the deal, Vor's stock price more than doubled in premarket trading, while RemeGen’s stock price in Hong Kong dropped 18% Thursday.
Angus Liu
Jun 26, 2025 10:55am
Argenx brews up ad for Vyvgart Hytrulo prefilled syringe in gMG
May 8, 2025 2:31pm
J&J's Imaavy wins FDA green light in myasthenia gravis
Apr 30, 2025 10:51am
FDA approves argenx's prefilled syringe version of Vyvgart
Apr 11, 2025 11:00am
Argenx banks on Vyvgart prefilled syringe approval in 2025: exec
Feb 19, 2025 1:36pm
Argenx sees early launch success for Vyvgart in CIDP
Nov 1, 2024 11:46am
